Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Safety Study in Indian ALK+ NSCLC Patients
NCT04541706Phase 4Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Treatment-Emergent Adverse Events up to 1.9 years. Started Aug 2020; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04541706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541706.